Introduction Lenvatinib (MK-7902) is a potent, oral, multi-targeted receptor tyrosine kinase inhibitor. It exerts its therapeutic effects by inhibiting key kinases involved in angiogenesis, tumor growth, and cancer progression, including VEGFR1-3, FGFR1-4, PDGFRA, KIT, and RET (1). Given its broad-spectrum activity, Lenvatinib has been investigated
264 Reached
Female with History of Amenorrhoea
3097 Reached10 Comments11 Likes
Role and Importance of DHA in Cognitive Development
524 Reached1 Likes
Woman with Complaint of Spontaneous Massive Rectal Prolapse
1867 Reached17 Comments9 Likes
Vildagliptin in Reducing Risk of Post-partum Diabetes
2386 Reached7 Comments4 Likes
Managing Amenorrhea in Adolescent girl
2548 Reached5 Comments4 Likes